Strumento inattivo

Azioni Dimension Therapeutics Inc

Azioni

Durata

Periodo

Stile

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”	02/10/17
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”	19/09/17
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx	18/09/17
Dimension Therapeutics : OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors	05/09/17
Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information	31/08/17

Dirigenti	Titolo	Età	Da
Thomas Kassberg PSD	President	63	07/11/17
Stephanie Haller CTO	Chief Tech/Sci/R&D Officer	-	01/11/14
Karah Parschauer BRD	Director/Board Member	46	07/11/17

Amministratori	Titolo	Età	Da
Karah Parschauer BRD	Director/Board Member	46	07/11/17

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3,30%	102 Mrd
REGENERON PHARMACEUTICALS, INC.	+1,79%	96,07 Mrd
ARGENX SE	-1,16%	21,66 Mrd
BIONTECH SE	-18,35%	20,77 Mrd
GENMAB A/S	-8,28%	18,53 Mrd
WUXI APPTEC CO., LTD.	-40,31%	16,91 Mrd
BEIGENE, LTD.	-26,84%	13,79 Mrd
NEUROCRINE BIOSCIENCES, INC.	+0,59%	13,33 Mrd
SAREPTA THERAPEUTICS, INC.	+20,86%	10,94 Mrd